Merck taps Italian CRO IRBM for peptide drug development

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/scyther5)
(Image: Getty/scyther5)

Related tags Merck & co MSD Peptide synthesis Peptides Contract research Contract research organization CRO

IRBM and Merck have signed a new agreement in the peptide therapeutics area through which the Italian CRO will identify potential peptide leads for a specific Merck target.

The Italy-headquartered contract research organization (CRO) IRBM has been collaborating with Merck & Co., Inc. (known as MSD outside the US and Canada) since 2010.

IRBM will be applying its capabilities in phage display peptide library design and screening, as well as in chemical peptide synthesis and optimization, according to the company.

“At MSD, evaluating the potential of peptide-based therapeutic candidates is a key part of our discovery strategy,” ​said Emma Parmee, VP of global discovery chemistry, MSD, ​in a press release.

“Our R&D peptide group have extensive expertise to help deliver high quality peptide drugs for a wide variety of therapeutic indications,” ​said Carlo Toniatti, CSO at IRBM. “We are thrilled to be collaborating on this project as part of our mission to advance impactful agents into the clinic.”

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Related suppliers

Follow us